-+ 0.00%
-+ 0.00%
-+ 0.00%

ELI LILLY: PLANS TO INITIATE PHASE 3 STUDIES OF ELORATZP CO-FORMULATION PRODUCT BY 2026 END USING OPTIMIZED ESCALATION SCHEDULE

Reuters·09/30/2026 14:15:00

Please log in to view news